Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrienX010 + Toripalimab in Resectable Melanoma
NCT04197882Phase 1Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orienx010 in melanoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Pathological Response Rates at 12 weeks and Clinical Effective Rate at 12 weeks. Status: unknown.
02
Drugs
orienx010
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04197882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197882.